Drug delivery platform for the local biological therapy of ocular inflammation

Bidragets beskrivning

Inflammation of the eye (also called uveitis) affects young adults aged 20-50 (sometimes also children) and can lead to blindness. Biological therapeutics are very effective in the treatment of ocular inflammation, however they must be administered systemically and can cause serious side-effects, including cancer. This project aims to develop a novel treatment that allows the safe and effective delivery of biological therapeutics directly to the eye. This local delivery is achieved by using short pieces of RNA called aptamers that can target the biological therapeutics to the inflammation site inside the eye.The method used to find these aptamers is called SELEX. Aptamer-targeted biological therapeutics are also embedded inside hydrogels, this allows their prolonged release and thus decreases the administration frequency. Overall, this project will develop a safer and more comfortable treatment for patients with ocular inflammation and thus decrease their risk of getting blind.
Visa mer

Startår

2020

Slutår

2026

Beviljade finansiering

Astrid Subrizi Orcid -palvelun logo
438 874 €

Andra beslut

336280
Akademiforskarens forskningskostnader(2020)
231 806 €

Finansiär

Finlands Akademi

Typ av finansiering

Akademiforskare

Övriga uppgifter

Finansieringsbeslutets nummer

333301

Vetenskapsområden

Farmaci

Forskningsområden

Farmasia

Identifierade teman

eyes, eye diseases